Download Free Medical Estrogens Progestins and Androgens PowerPoint Presentation

Estrogens Progestins and Androgens PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on cancer titled "Estrogens, Progestins and Androgens" to get an overview of Estrogens, Progestins and Androgens.

Tags : Cancer, Overview, Estrogens, Therapeutic Formulations, Uses, Progestins, Contraception, Androgens, Endocrine Physiology, Molecular Mechanisms

Published on : May 05, 2021 | Views : 1890 | Downloads : 1

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Estrogens, Progestins and Androgens Becky Worthylake bworth@lsuhsc.edu
Slide 2-

Outline Overview Estrogens – General Estrogens & Modifiers – Therapeutic Formulations & Uses Progestins – Therapeutic Formulations & Uses Contraception Androgens – General Androgens – Uses & Therapeutic Formulations
Slide 3-

Hypothalamus (GnRH) & Pitutary Luteinizing Hormone & Follicle Stimulating Hormone Ovaries & Testes Reproduction Overview: Endocrine Physiology
Slide 4-

Overview: Molecular Mechanisms
Slide 5-

Overview: Molecular Mechanisms
Slide 6-

Outline Estrogens – General Synthesis Physiology Regulation
Slide 7-

Cholesterol Pregnenolone Estradiol OH OH OH A B C D 1 2 3 4 5 6 7 8 9 10 CH 3 11 19 12 13 14 15 16 17 18 CH 3 CH 2 CH 3 CH CH 2 CH 2 CH 2 CH 3 CH 3 20 21 23 22 24 25 27 28 Testosterone DHEA Androstenedione Progesterone Androstenedione aromatase Synthesis
Slide 8-

Physiology
Slide 9-

FSH, LH Same a Different b Regulation: Feeback Loops
Slide 10-

Regulation : Circulating Levels
Slide 11-

Follicular Luteal Regulation: Impact on Reproductive Tissues
Slide 12-

Outline Estrogens & Estrogen Modifiers – Therapeutic Formulations and Uses Therapeutic Estrogens SERMs (selective estrogen receptor modulators) Estrogen Synthesis Inhibitors
Slide 13-

Therapeutic Estrogens Indications Primary Hypogonadism Postmenopausal Hormonal Therapy Oral Contraceptives Suppress ovulation in patients with intractable dysmenorrhea or hirsutism Fertility treatments
Slide 14-

Side effects Nausea, fluid retention, breakthrough bleeding, change in menstrual flow, breast tenderness. Adverse Effects: Thrombolytic complications; endometrial carcinoma; breast carcinoma; and hypertension. In men - feminization of genitalia & impotence. Contraindications: Pregnancy, incomplete bone growth, undiagnosed genital bleeding; stroke, thrombophlebitis, or thromboembolic disease., heart disease. Women with family history of breast or uterine cancer (BRCA gene) Drug Interactions:  efficacy of oral anticoagulants and hypoglycemic agents  adverse effects of tricyclic antidepressants  the effects of oxytocin on the uterus. St. John's wort may cause loss of contraceptive or hormonal-replacement efficacy of estrogens Therapeutic Estrogens Cont’
Slide 15-

Uses: HRT – Symptoms of Menopause  LH, FSH Estrone is major Estrogen GnRH Normal, Midcycle Normal Postmenopausal GnRH HDL/LDL ratio
Slide 16-

(Increased risk of MI and stroke, especially in the first year) Uses : HRT – Effects of Treatment
Slide 17-

Early HRT used estrogen alone: increased risk of uterine (endometrial) cancer. As a result, addition of progestins is now used to limit endometrial hyperplasia Medroxyprogesterone (MPA) acetate is most commonly used Various regimens are used: estrogen for 25 days with inclusion of MPA during last 10-13 days of estrogen, 5-6 days with no hormones Combination formulations: PREMPRO (PREMARIN plus MPA) given at fixed dose daily; PREMPHASE (PREMARIN for 28 days and MPA for days 14-28) Newer combos of estrogens with progestins: FEM HRT (estradiol plus norethindrone acetate) ORTH PREFEST (estradiol plus norgestimate) Vaginal creams (PREMARIN) or a ring device (ESTRING) can be used instead of oral doses . Reduces vaginal dryness, yeast infections and urinary tract infections. Uses: HRT - Formulations
Slide 18-

SERMs (Selective Estrogen Receptor Modulators) Selectivity is possible because ER- and/or ER- show differential tissue expression. Conformation dependent binding to DNA and transcription factors Tissue dependent responses ranging between pro-estrogenic, partially estrogenic and anti-estrogenic effects
Slide 19-

SERMs: Tamoxifen – Breast Cancer 2-3 fold increased risk of deep vein thrombosis & pulmonary embolism
Slide 20-

- Most effective in treatment of tumors that are ER-positive (50% response) or ER + PR positive (70-80% response rates). Responses of ER-negative tumors is < 10%. Adjuvant therapy with chemo or radiation in treatment - Preventative agent for women at high risk for breast cancer. Resistance is usually developed in 5 years, which may, in part, reflect alterations in the ER receptors in the tumors. SERMs: Tamoxifen continued
Slide 21-

Raloxifene (EVISTA): - High affinity for both ER- and ER- Treatment of osteoporosis in post-menopausal women. Does not cause proliferation of the endometrium or breast tumor cells Side effects: 2-3 fold  risk of deep vein thrombosis and pulmonary embolism Interactions: Ampicillin  absorption Raloxifene  warfarin efficacy SERMs: Other
Slide 22-

Clomiphene Weak agonist and strong antagonist for ER- or ER-. Oppose the negative feedback effects of endogenous estrogen. amplitude of the LH and FSH pulses - Major use: induction of ovulation in women with an intact hypothalamic-pituitary-ovarian axis Adverse effects: multiple births, ovarian cysts ICI 182,870 Fulvestrant (FASLODEX) - pure estrogen antogonist - effective in treating tamoxifen-resistant tumors Anti-Estrogens
Slide 23-

Steroidal: exemestane (AROMASIN) Non-steroidal: anastrozole (ARIMIDEX), letrozole (FEMARA) - Specifically block the local production of estrogens in hormonally-responsive tissues. - Second-line treatment for breast cancer in patients whom tamoxifen therapy is unsuccessful, but new studies rapidly proving its efficacy and promoting earlier use - Aromatase inhibitors do not have the bone protecting activity of tamoxifen, and adjuvant therapies to prevent bone loss are in trials Estrogen Synthesis Inhibitors
Slide 24-

Progestins – Therapeutic Formulations & Uses Therapeutic Progestins anti-Progesterones Outline
Slide 25-

Naturally occurring progesterone (low oral bioavailability) - Micronized particles suspended in oil and packaged in gelatin capsules (PROMETRIUM) - Vaginal gel (CRINONE) - Slow-release intrauterine device (PROGESTASERT) 17-a-hydroxy-progesterone derivatives have substitutions at C17 that slow hepatic metabolism : medroxyprogesterone (MPA) (PROVERA) 19-nor testosterone derivatives display primarily progestational rather than androgenic activity : norethindrone Replacement of the 13-methyl group of norethindrone with a 13-ethyl substituent are more potent progestins and less androgenic: norgestrel, nomegestrol Progestins – Therapeutic Progesterone
Slide 26-

Mechanism of Action: Interacts with PR to mimic the stimulatory affects of progesterone Physiological Target: Reproductive Tract Decreases estrogen-driven endometrial proliferation Establishment and maintenance of pregnancy Common Uses: - Oral contraceptives - HRT to limit estrogen’s effects on the endometrium - Uterine Bleeding disorders Premature labor (decrease uterine contractions) Stimulate Appetite in AIDS or cancer patients Progestins continued
Slide 27-

Progestins: anti-Progesterones Mifepristone (RU 486) (mifeprex): PR antagonist Used in first trimester to terminate pregnancy (along with prostaglandins to increase uterine contractions) Post-coital contraceptive (prevent implantation) Investigational: induction of labor after fetal death and treatment of endometriosis. Adverse Effects: vaginal bleeding, abdominal pain and cramping Contraindicated in patients with vaginal bleeding, adrenal dysfunction or asthma (due to anti-glucocorticoid actions) Interactions: Decreases efficacy of anticoagulants. Inhibits hepatic metabolism by CYP3A4 (eg.anti-retroviral protease inhibitors, calcium-channel blockers, carbamazepine)
Slide 28-

Outline Contraception Therapeutic Estrogens & Progesterones Oral Contraceptive Formulations Emergency Contraception Extended-Regimen Contraception Mechanism of Action Effects
Slide 29-

Contraception
Slide 30-

Oral Contraceptives: History 1950: Pincus et al (progesterone prevents ovulation) 1959: 1st pill appeared in USA 1960: mini pill (progesterone alone) 1970: Introduction low dose or second generation of OCS 1980: biphasic or triphasic regimens 1990: 3rd generation OCs e.g, norgestimate 0.25mg or desogestrel 0.15 mg)
Slide 31-

Contraception: Therapeutic Estrogens 1. Estrogens: mestranol and ethinyl estradiol Hepatic Metabolism Absorbed efficiently in GI tract. Mestranol is biologically inactive and must be metabolized to ethinyl estradiol. Peak plasma levels within 1 hr after oral administration Clearance is ~ 60% 24 hr after oral dose Ethinyl estradiol is 2X more potent than mestranol
Slide 32-

Contraception: Therapuetic Progestins 19-NOR Steroids :Progestins Removal of 19-carbon changed major hormonal effect from an androgen to progestin while maintaining oral activity Estranes: have some androgenic activity as well as estrogenic/anti- estrogenic actions. Rapidly absorbed (Norethindrone)
Slide 33-

OH CH 2 C CH O H 3 C H H H DESOGESTREL H2C Gonanes: More potent than estranes and less androgenic activity and are now used in the 3rd generation combination oral contraceptives (Norgestrel, Norgestimate, Desogestrel) Contraception: Therapuetic Progestins cont’
Slide 34-

• 1st generation: products containing mestranol Low dose OCs: products containing < 50 mcg ethinyl estradiol • 2nd generation “Low-Dose” : products containing gonanes (levonorgestrel, norgestimate) and other members of norethindrone family and 20, 30, or 35 mcg ethinyl estradiol • 3rd generation: desogestrel or gestodene (new progestins) with 20, 30, or 35 mcg ethinyl estradiol Therapeutic Estrogen & Progestin Combinations
Slide 35-

Monophasic: The concentrations of estrogens and progestins are fixed in the pill, which is taken for 21 days followed by 7 days of “hormone-free” pills. mestranol (50 µg) + norethindrone (1.0 mg) (ORTHO-NOVUM 1/50, NORINYL 1+50) b. ethinyl estradiol (20-30 µg) + a progestin (estranes or the gonanes, 0.15-1.5 mg). Include ORTHO-NOVUM 1/35, NORDETTE, ORTHO-CEPT , LOESTRIN) Contraception: Formulations
Slide 36-

ethinyl estradiol (fixed concentration) + norethindrone (lower concentration in the first 7-10 days and then higher concentration for the next 11-14 days). (Include ORTHO-NOVUM 10/11, JENEST-28) The rationale is to limit exposure to the higher concentration of the progestin. Biphasics: Contraception: Formulations
Slide 37-

Fixed concentration of ethinyl estradiol with 3 different concentrations of norethindrone (TRI-NORINYL ORTHO-NOVUM 7/7/7), Fixed concentration of ethinyl estradiol with three concentrations of gonanes. (ORTHO-TRI-CYCLEN - norgestimate; TRI-LEVLEN, TRIPHASIL - levonorgestral ). Rationale is to mimic the hormonal changes in the menstrual cycle Triphasic: Contraception: Formulations
Slide 38-

Oral formulations of norethindrone (micronor) or levonorgestrel (ovrette) taken daily Subdermal implants of levonorgestrel (norplant) for slow-release and long-term contraceptive actions (up to five years) IM injections of medroxyprogesterone (depo-provera) that provides effective contraception for 3 months IUD that releases low amounts of progesterone locally (progestasert). Contraception: Formulations Progestin Only:
Slide 39-

Drugs used for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. Emergency hormone contraceptive regimens are highly effective and decrease the risk of pregnancy by 75 percent To be effective these must be taken within 72 hours of intercourse May also inhibit ovulation or fertilization depending on timing of administration Alteration of the endometrium, sperm penetration, and tubal motility are also affected . ESTABLISHED PREGNANCIES ARE NOT HARMED. Two products are available: Plan B: 0.75 mg levonorgestrel Preven: 0.25 mg levonorgestrel and 0.05 mg ethinyl estradiol (this product includes a pregnancy test kit) Emergency Contraceptives
Slide 40-

Advantages • Period once every 3 months • Period last about 3 days with decreased bleeding , Side Effects: Breakthrough bleeding and spotting Levonorgestrel / ethinyl estradiol 0.15 mg / 0.03 mg And either placebo or ethinyl estradiol tablets 0.01 mg tablets) Brand Names: Jolessa, Quasense, Seasonale, Seasonique 91-day courses of tablets Seasonique: incorporates low-dose estrogen rather than placebo tablets in an effort to limit bloating, hormonal fluctuations, and breakthrough bleeding. Extended Regimen Contraception
Slide 41-

Contraceptives: MOA LH/FSH release  Follicular development & ovulation
Slide 42-

Progestin only: Thick cervical mucus Implantation of blastocyst in endometrium Contractions of uterus & F.tubes are modified Contraceptives: MOA
Slide 43-

• Start First day of next menstrual period • Some suggest starting on first Sunday following onset of menses – Usually avoids menstrual period on weekends – Most clinicians recommend backup for at least 2 cycles Initiating Method Other Beneficial effects 1. Decreases Dysmenorrhea 2. Decreases benign breast and ovarian cysts 3. Regulates cycle in anovulatory women 4. Decreased blood loss during menstruation 5. 50% reduction in ovarian and endometrial cancer. Effects: Benefits
Slide 44-

Drugs that disrupt liver metabolism and increase oral contraceptive metabolism - anti-seizure medications, St. John’s wort - antibiotics tetracycline and ampicillin - HIV protease inhibitors - Anti-tuberculosis drugs such as rifampin Oral contraceptives effect the activity of other drugs a. anticoagulants b. benzodiazepines, c. beta-blockers d. corticosteroids, and tricyclic antidepressants Effects: Drug Interactions
Slide 45-

Absolute a. History of thromboembolism, MI, stroke b. Impaired liver function c. Known or suspected breast cancer d. Undiagnosed abnormal vaginal bleeding e. Known or suspected pregnancy f. Smokers over age 35 (may use progestin-only) 2. Relative a. – Migraine headaches b. – Hypertension - ok if <35, or healthy, or BP controlled c. – Elective surgery: Discontinue 4wks. prior to major surgery d. – Gallstones/ Cholecystitis e. – Epilepsy: anti-seizure meds may decrease effectiveness of OCP’s f. – Diabetes: small risk or worsening vascular disease. Effects: Contraindications
Slide 46-

Outline Androgens – General Synthesis Regulation Physiological Effects
Slide 47-

Androgens : Synthesis
Slide 48-

Androgens : Regulation
Slide 49-

Androgens : Regulation Circulating testosterone and dihydrotestosterone 1-2% Free 65% bound to SSBG (sex steroid binding globulin) 33-34% bound to albumin
Slide 50-

Androgens : Physiology
Slide 51-

Outline Androgens – Uses & Therapeutics Treatable Conditions Therapeutic Formulations of Testosterones and Androgens Androgen Antagonists
Slide 52-

Male hypogonadism: develop or maintain secondary sex characteristics B. Andropause Prostate Cancer Male Pattern Baldness Treatable Conditions
Slide 53-

Condition: Adult Male Hypogonadism Symptoms Decreased libido Erectile dysfunction Infertility Fatigue, weakness Depression, loss of motivation, irritability Vasomotor phenomena Signs Decreased body hair Decreased muscle mass Small prostate and testes Gynecomastia Osteoporosis Anemia Treatment Transdermal testosterone esters Monitoring for both beneficial and deleterious effects required, age dependent
Slide 54-

Condition: Andropause Changes are slower and more subtle: progressive decline (total and free) in testosterone levels   Leydig cell number and activity. ~ 60% of healthy men over 65 have lower testosterone compared to 20-35 year old men and may be related to impotence Treatment: Pharmacological doses of testosterone in men  muscle mass and muscle strength especially in combination with exercise. Also  cognition and sense of well being. Negative Effects: Lipid profiles (LDL),  prostate size, uninary symptoms New Developments: “STRM” selctive androgen recepotor modulators: Goal is to have anabolic effect on muscle mass and anti-androgenic effect on the prostate
Slide 55-

17-a-alkylated androgens: decreased breakdown by liver, but can elicit hepatic toxicity Testosterone derivatives Testosterone (HISTERONE) oral admin. leads to absorption into the hepatic circulation and rapid catabolism Effective in transdermal patches Theraputic Formulations: Testosterones
Slide 56-

17a Hydroxyl Group Esters More lipophilic than testosterone Converted to testosterone in the circulation Testosterone enanthate (Delatestryl®) Given IM once every two weeks Testosterone undecanoate (Andriol®) Absorbed into lymphatic system when taken orally (40 mg capsules) Testosterone propionate (Neo-Hombreol®) Short duration of action (i.e. 1-2 days) even when delivered IM Theraputic Formulations: Androgens
Slide 57-

17a Alkylated Testosterone Hepatic metabolism retarded Reduced androgenicity Somewhat hepatotoxic Methyltestosterone (Metandren®) Taken orally (e.g. 10-50 mg/day in men, 5-25 mg/day for 4-6 months in children) Theraputic Formulations: Androgens
Slide 58-

Potential Side Effects of Excessive Androgen Treatment Reduced spermatogenesis and fertility due to feedback inhibition of LH and FSH secretion from anterior pituitary Acne, particularly in women due to androgen stimulation of sebaceous glands beneath skin Virilization (including facial hair and hirsutism) in women and children In older men, increased risk of benign prostate hyperplasia and prostate cancer Hepatotoxicity (for 17a-alkylated androgens) Theraputic Formulations: Side Effects Anabolic Steroid and Androgen Abuse in Sports 100-200 x normal daily production in men
Slide 59-

Androgen Receptor antagonists Flutamide (EVLEXIN) and Bicalutamide (CASODEX). Bicalutamide has much less hepatoxicity Used in conjunction with GnRH analogs to treat metastatic prostate cancer Treat Hirsutism in women (due to hepatoxicity should not use for cosmetic purposes) 5-a-reductase inhibitors Finasteride (PROSCAR) used to treat benign prostatic hypertrophy and male patterned baldness (PROPECIA) Androgen Antagonists